Physician profile
Daniel B Levy
NPI 1467470047
$2,557.20
in general payments reported to CMS, 2019-2025
19 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $244 · 2021: $237 · 2022: $462 · 2023: $307 · 2024: $308 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $882.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $567.74 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $506.10 | 2021-2025 | |
| Viiv Healthcare Company | $367.32 | 2019-2024 | Cabenuva, Dovato |
| Gilead Sciences, INC. | $362.30 | 2019 | |
| Ironshore Pharmaceuticals INC. | $161.63 | 2023 | Jornay Pm |
| Cranial Technologies, INC | $105.95 | 2021-2023 | Doc Band |
| Supernus Pharmaceuticals, INC. | $101.35 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.34 | 2019-2020 | |
| Lilly USA, LLC | $50.49 | 2020-2025 | Mounjaro, Zepbound |
| Janssen Biotech, INC. | $46.40 | 2019 | |
| Allergan, INC. | $45.24 | 2020 | |
| Merck Sharp & Dohme LLC | $28.65 | 2019 | |
| Astellas Pharma US INC | $26.95 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.28 | 2019-2020 | |
| Pfizer INC. | $24.41 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $17.54 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $14.24 | 2019 | |
| Insmed, INC. | $12.89 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.